Evercore ISI resumed coverage of Becton Dickinson (BDX) with an Outperform rating and $180 price target Becton Dickinson is in a transition year with the biosciences and diagnostics separation and a series of transitory headwinds “masking a more stable underlying growth profile,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BD’s PosiFlush SafeScrub Study Completion: What Investors Should Watch Next
- Becton Dickinson price target lowered to $159 from $170 at Piper Sandler
- Becton Dickinson price target lowered to $175 from $195 at RBC Capital
- Nike downgraded, IBM initiated: Wall Street’s top analyst calls
- Becton Dickinson resumed with a Neutral at Goldman Sachs